Annandale, VA; June 29, 2020
CARE-ID has begun recruiting and treating patients in a clinical research study to evaluate the safety and effectiveness of LY-CoV555 in patients with early mild to moderate COVID-19. Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful laboratory studies. CARE-ID is looking for adults ages 18 or older to participate in this study who have recently tested positive for COVID-19 and are not hospitalized.